Small-cell transformation in EGFR‑mutant lung cancer
In most patients with EGFR‑mutant lung cancer, modern targeted medicines such as osimertinib work remarkably well. They can keep the
November 22, 2025
New approaches in small-cell lung cancer: strong first responses, faster relapses, and how maintenance therapy may help
Small-cell lung cancer is striking for its dramatic initial response to treatment. With standard platinum-based chemotherapy, 85 to 90 percent